Becker's Hospital Review7d
Wegovy reduces all-cause admissions: 3 study findings
Findings presented Nov. 3 during a session at the annual ObesityWeek conference showed admissions for any cause occurred in 33.4% of patients taking Wegovy, compared to nearly 37% in the placebo ...
Novo Nordisk’s Wegovy Sales Increase Reassures Investors
Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt last quarter as it became available in more ...
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...
Bloomberg L.P.9d
Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...